216 related articles for article (PubMed ID: 25306466)
1. Interleukin-15: new kid on the block for antitumor combination therapy.
Van den Bergh JM; Van Tendeloo VF; Smits EL
Cytokine Growth Factor Rev; 2015 Feb; 26(1):15-24. PubMed ID: 25306466
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 15 as a promising candidate for tumor immunotherapy.
Jakobisiak M; Golab J; Lasek W
Cytokine Growth Factor Rev; 2011 Apr; 22(2):99-108. PubMed ID: 21531164
[TBL] [Abstract][Full Text] [Related]
3. IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation.
Van den Bergh JM; Lion E; Van Tendeloo VF; Smits EL
Pharmacol Ther; 2017 Feb; 170():73-79. PubMed ID: 27777088
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-based therapy and biochemotherapy for advanced melanoma.
Atkins MB
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2353s-2358s. PubMed ID: 16609058
[TBL] [Abstract][Full Text] [Related]
5. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
6. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
7. The potential and promise of IL-15 in immuno-oncogenic therapies.
Robinson TO; Schluns KS
Immunol Lett; 2017 Oct; 190():159-168. PubMed ID: 28823521
[TBL] [Abstract][Full Text] [Related]
8. Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?
Zdrenghea MT
Med Hypotheses; 2013 Aug; 81(2):311-5. PubMed ID: 23669372
[TBL] [Abstract][Full Text] [Related]
9. IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances.
Shanmugham LN; Petrarca C; Frydas S; Donelan J; Castellani ML; Boucher W; Madhappan B; Tete' S; Falasca K; Conti P; Vecchiet J
J Exp Clin Cancer Res; 2006 Dec; 25(4):529-36. PubMed ID: 17310844
[TBL] [Abstract][Full Text] [Related]
10. Biologic therapy of melanoma with cytokines and lymphocytes.
Bear HD; Hamad GG; Kostuchenko PJ
Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2: solid-tumor therapy.
Oppenheim MH; Lotze MT
Oncology; 1994; 51(2):154-69. PubMed ID: 8196899
[TBL] [Abstract][Full Text] [Related]
13. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
[TBL] [Abstract][Full Text] [Related]
14. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-15 gene therapy and the mammalian target of rapamycin inhibitor everolimus inhibit the growth of metastatic breast cancer.
Zhao N; Li X; He X; Qiu Y; Zhu L; Qi F
J Gene Med; 2013 Oct; 15(10):366-74. PubMed ID: 24038990
[TBL] [Abstract][Full Text] [Related]
16. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
17. IL-15: targeting CD8+ T cells for immunotherapy.
Diab A; Cohen AD; Alpdogan O; Perales MA
Cytotherapy; 2005; 7(1):23-35. PubMed ID: 16040381
[TBL] [Abstract][Full Text] [Related]
18. The IL-2 cytokine family in cancer immunotherapy.
Sim GC; Radvanyi L
Cytokine Growth Factor Rev; 2014 Aug; 25(4):377-90. PubMed ID: 25200249
[TBL] [Abstract][Full Text] [Related]
19. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
Sinkovics JG
Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?
Perez-Gracia JL; Berraondo P; Martinez-Forero I; Alfaro C; Suarez N; Gurpide A; Sangro B; Hervas-Stubbs S; Ochoa C; Melero JA; Melero I
Immunotherapy; 2009 Sep; 1(5):845-53. PubMed ID: 20636027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
